国际呼吸杂志
國際呼吸雜誌
국제호흡잡지
INTERNATIONAL JOURNAL OF RESPIRATION
2008年
10期
590-592,封3
,共4页
肺癌%基质金属蛋白酶9%基因治疗%反义寡核苷酸
肺癌%基質金屬蛋白酶9%基因治療%反義寡覈苷痠
폐암%기질금속단백매9%기인치료%반의과핵감산
Lung cancer%Matrix metalloproteinase-9%Gene therapy%Antisense oligodeoxynucleotide
目的 探讨以基质金属蛋白酶9(matrix metalloproteinase-9,MMP-9)为靶点反义基因治疗人 肺腺癌移植瘤的可行性.方法 常规体外培养A549细胞,采用皮下注射法建立移植瘤裸鼠动物模型.裸鼠成瘤后,随机分为4组.以脂质体(liposome,Lip)包裹的MMP-9反义寡核苷酸(antisense oligodeoxynucleotide,ASODN)直接移植瘤内注射,观察肿瘤生长情况,计算抑瘤率和肿瘤生长指数,并观察对心、肝、肾组织有无毒副作用.结果 MMP-9 ASODN/Lip组肿瘤生长指数为3.20±0.14,明显低于其他三组(MMP-9 SODN/Lip组为5.93±0.20,Lip组为5.874±0.02,对照组为6.40±0.33)(P＜0.01);MMP-9 ASODN/Lip组的瘤重为(1.25±0.03)g,明显低于其他三组[MMP-9 SODN/Lip组为(2.15±0.07)g,Lip组为(2.31±0.04)g,对照组为(2.43±0.04)g](P＜0.01);MMP-9 ASODN/Lip组抑瘤率为(33.41±1.18)%,心、肝、肾组织结构基本正常.结论 MMP-9 ASODN可以抑制人肺腺癌移植瘤的生长,对心、肝、肾组织无明显不良反应;特异性靶向MMP-9 ASODN可能成为肺癌的辅助治疗方法.
目的 探討以基質金屬蛋白酶9(matrix metalloproteinase-9,MMP-9)為靶點反義基因治療人 肺腺癌移植瘤的可行性.方法 常規體外培養A549細胞,採用皮下註射法建立移植瘤裸鼠動物模型.裸鼠成瘤後,隨機分為4組.以脂質體(liposome,Lip)包裹的MMP-9反義寡覈苷痠(antisense oligodeoxynucleotide,ASODN)直接移植瘤內註射,觀察腫瘤生長情況,計算抑瘤率和腫瘤生長指數,併觀察對心、肝、腎組織有無毒副作用.結果 MMP-9 ASODN/Lip組腫瘤生長指數為3.20±0.14,明顯低于其他三組(MMP-9 SODN/Lip組為5.93±0.20,Lip組為5.874±0.02,對照組為6.40±0.33)(P＜0.01);MMP-9 ASODN/Lip組的瘤重為(1.25±0.03)g,明顯低于其他三組[MMP-9 SODN/Lip組為(2.15±0.07)g,Lip組為(2.31±0.04)g,對照組為(2.43±0.04)g](P＜0.01);MMP-9 ASODN/Lip組抑瘤率為(33.41±1.18)%,心、肝、腎組織結構基本正常.結論 MMP-9 ASODN可以抑製人肺腺癌移植瘤的生長,對心、肝、腎組織無明顯不良反應;特異性靶嚮MMP-9 ASODN可能成為肺癌的輔助治療方法.
목적 탐토이기질금속단백매9(matrix metalloproteinase-9,MMP-9)위파점반의기인치료인 폐선암이식류적가행성.방법 상규체외배양A549세포,채용피하주사법건립이식류라서동물모형.라서성류후,수궤분위4조.이지질체(liposome,Lip)포과적MMP-9반의과핵감산(antisense oligodeoxynucleotide,ASODN)직접이식류내주사,관찰종류생장정황,계산억류솔화종류생장지수,병관찰대심、간、신조직유무독부작용.결과 MMP-9 ASODN/Lip조종류생장지수위3.20±0.14,명현저우기타삼조(MMP-9 SODN/Lip조위5.93±0.20,Lip조위5.874±0.02,대조조위6.40±0.33)(P＜0.01);MMP-9 ASODN/Lip조적류중위(1.25±0.03)g,명현저우기타삼조[MMP-9 SODN/Lip조위(2.15±0.07)g,Lip조위(2.31±0.04)g,대조조위(2.43±0.04)g](P＜0.01);MMP-9 ASODN/Lip조억류솔위(33.41±1.18)%,심、간、신조직결구기본정상.결론 MMP-9 ASODN가이억제인폐선암이식류적생장,대심、간、신조직무명현불량반응;특이성파향MMP-9 ASODN가능성위폐암적보조치료방법.
Objective To explore the feasibility of antisense oligodeoxynucleotide(ASODN)targeting matrix metalloproteinase-9(MMP-9)gene for human lung adenocarcinoma xenograft in nude mice.Methods Cell lines A549 were cultured routinely with RPMI 1640 medium.A549 cells were subcutaneously implanted in nude mice to establish xenograft animal models.After MMP-9 ASODN mediated by cytofectin was directly imected into xenograft in 5 places,the volumes and mass of tumor mass were detected,respectively,and then tumor growth inhibitory rate and tumor growth index were calculated.Results Tumor growth index in MMP-9 ASODN/Liposome(Lip)group was 3.20±0.14,which was less than other three groups(5.93±0.20,5.87±0.02 and 6.40±0.33)(P＜0.0t).The tumor mass in MMP-9 ASODN/Lip group was(1.25±0.03)g,which was less than other three groups[(2.15±0.07)g,(2.31±0.04)g and (2.43±0.04)g](P＜0.01).The inhibition rate of tumor in MMP-9 ASODN/Lip group was(33.41±1.18)%.There were no obvious tissue damages in heart,liver and kidney.Conclusions MMP-9 ASODN mediated by cytofectin can inhibit the tumor growth by direct intratumoral injection and no adverse effect.ASODN targeting MMP-9 gene can be a supportive therapy method of lung cancer.
